Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versushost disease by Joseph Pidala, Jongphil Kim, Melissa Alsina, Ernesto Ayala, Brian C. Betts, Hugo F. Fernandez, Teresa Field, Heather Jim, Mohamed A. Kharfan-Dabaja, Frederick L. Locke, Asmita Mishra, Taiga Nishihori, Leonel Ochoa-Bayona, Lia Perez, Marcie Riches, and Claudio Anasetti haematol Volume 100(7): 970 -977 June 30, 2015 © 2015 by Ferrata Storti Foundation

Cumulative incidence of NIH Consensus moderate-severe chronic graft-versus-host disease. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation

Comparative distribution of maximal chronic graft-versus-host disease organ involvement and severity. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation

Cumulative incidence of late acute graft-versus-host disease. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation

Late acute graft-versus-host disease characteristics and severity. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation

Comparison of prednisone exposure over time. *Prednisone dose presented as mean values for SIR/TAC and MTX/TAC groups for each time point. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation

Cumulative incidence of successful TAC discontinuation. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation

Causes of death. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation

Failure-free survival for chronic graft-versus-host disease cohort. Joseph Pidala et al. Haematologica 2015; 100: 970 -977 © 2015 by Ferrata Storti Foundation